Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $32.25

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus rating of “Buy” from the nine analysts that are presently covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $32.25.

Several equities research analysts have commented on the stock. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price objective for the company. Stephens started coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Finally, Truist Financial raised their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Castlekeep Investment Advisors LLC bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $37,494,000. Bank of America Corp DE lifted its holdings in shares of Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock worth $32,741,000 after acquiring an additional 913,843 shares during the period. abrdn plc bought a new position in Catalyst Pharmaceuticals during the 4th quarter valued at about $10,115,000. Arrowstreet Capital Limited Partnership lifted its holdings in Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock valued at $14,570,000 after purchasing an additional 396,506 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after acquiring an additional 390,116 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:CPRX opened at $21.25 on Thursday. The firm’s 50 day moving average is $22.25 and its two-hundred day moving average is $21.39. Catalyst Pharmaceuticals has a 52 week low of $13.91 and a 52 week high of $24.64. The firm has a market capitalization of $2.53 billion, a P/E ratio of 18.01, a PEG ratio of 3.31 and a beta of 0.80.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.